How many patients with MS do you have personally under your care:

Of your [MS PT #] MS patients, how many patients do you currently have on the following treatments:

• Ocrevus
• Kesimpta
• Briumvi

What is your general view of BRIUMVI?  What role, if any, do you see BRIUMVI playing in your practice?

Please comment on any meaningful efficacy or safety difference that you perceive between Ocrevus & BRIUMVI?

From your first-hand clinical experience so far, does BRIUMVI offer superior, inferior, or similar infusion tolerability compared with OCREVUS?

Please elaborate on your answer above. Please be specific.

What percentage (%) of your patients who were on Ocrevus prior to BRIUMVI's launch do you think will end up switching to BRIUMVI by the end of 2024 ( ~within 18 months) due to the following:

• Due primarily to superior perceived efficacy and/or safety
• Due primarily to superior perceived tolerability
• Due primarily to 1-hour infusion time advantage
• Due primarily to BRIUMVI not having a warning for breast cancer on its label
• Due to any or all reasons

Please elaborate on your answer above. Please be specific.

Of your patients who will be newly prescribed an anti-CD20 drug for the first time and who will be making a decision between Ocrevus & BRIUMVI, what percentage (%) of them will choose BRIUMVI over OCREVUS due to the following:

• Due primarily to superior perceived efficacy and/or safety
• Due primarily to superior perceived tolerability
• Due primarily to 1-hour infusion time advantage
• Due primarily to BRIUMVI not having a warning for breast cancer on its label
• Due to any or all reasons

Please elaborate on your answer above. Please be specific.

Does BRIUMVI's 1-hour infusion time make a difference to the operating effectiveness of the infusion centers you work with?  If so, will that factor into whether you choose to prescribe BRIUMVI or  OCREVUS? Please elaborate.

Is your ability to prescribe BRIUMVI gated by the existence of an institutional formulary at the center where you work, and if so how has the past and expected future positioning of BRIUMVI on that formulary impacted your past and future plans to use BRIUMVI? Please elaborate.

To what extent is additional work required by you (or your staff) to get patients approved by insurance for BRIUMVI vs. OCREVUS, and does this play a role in your willingness to prescribe BRIUMVI over OCREVUS? Please elaborate.

Of the [Briumvi PT # Response] patients you have on Briumvi today, how many of those came as switches from Ocrevus over the past 6 months:

Relative to the [Previous Response] patients you switched from Briumvi to Ocrevus over the past 6 months, how many patients do you plan to switch from Ocrevus to BRIUMVI over the next 6 months:

Over the past 6 months, how many NEW to anti-CD20 patients did you start on:

Over the next 6 months, how many NEW to anti-CD20 patients do you plan to start on:

Please elaborate on any specific reasons you envision increasing or decreasing your total usage of BRIUMVI over the next 6 months?  Please be as specific as possible.

You mentioned that you have [Sum of Anti-CD20 pt #] total patients on the three branded ANTI-CD20 drugs today. How many patients IN TOTAL do you expect to have on these three drugs at the following points in time:

• 6 months from now
• 1 year from now
• 3 years from now

You mentioned that you currently have [Briumvi Pt #] patients on Briumvi. How many patients TOTAL do you expect to have ON BRIUMVI at the following points in time:

• 6 months from now
• 1 year from now
• 3 years from now